Study of Chemotherapy Combination With Autologous Cell Immunotherapy in the Recurrent and Metastatic Colorectal Cancer
Status:
Recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
This study evaluates the effect and safty of PD-1 monoclonal antibody-activated autologous
peripheral blood lymphocyte (PD1-T) combined with XELOX and bevacizumab in the first-line
treatment of recurrent and metastatic colorectal cancer. Half of participants receive PD1-T
combined with XELOX and bevacizumab, while the other half will receive XELOX and bevacizumab.
Phase:
Phase 3
Details
Lead Sponsor:
Tianjin Medical University Cancer Institute and Hospital